247564-55-2

Usage

Uses

Used in Pharmaceutical Industry:
4,7-DIFLUOROINDOLE is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and potential biological activities make it a valuable component in the development of new drugs and therapeutic agents.
Used in Anticancer Research:
4,7-DIFLUOROINDOLE is used as a potential anti-cancer agent. It has been studied for its potential role in inhibiting the growth and progression of cancer cells, making it a promising candidate for further research and development in oncology.
Used in Fluorescent Probes:
4,7-DIFLUOROINDOLE is used as a fluorescent probe for detecting hydrogen peroxide in living cells. Its fluorescent properties allow for the visualization and monitoring of reactive oxygen species, which are important in various biological processes and disease mechanisms.
Used in Materials Science:
4,7-DIFLUOROINDOLE is used as a precursor for the preparation of fluorescent polymers. Its unique structure and properties make it a valuable component in the development of new materials with potential applications in various fields, such as sensors, imaging, and optoelectronics.

InChI:InChI=1/C8H5F2N/c9-6-1-2-7(10)8-5(6)3-4-11-8/h1-4,11H

Upstream product

• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 1393735-83-5 N-(6-nitroveratryloxycarbonyl)-4,7-difluorotryptophan cyanomethyl ester 

Relevant academic research and scientific papers

Ondansetron and granisetron binding orientation in the 5-HT3 receptor determined by unnatural amino acid mutagenesis

The serotonin type 3 receptor (5-HT3R) is a ligand-gated ion channel found in the central and peripheral nervous systems. The 5-HT 3R is a therapeutic target, and the clinically available drugs ondansetron and granisetron inhibit receptor activity. Their inhibitory action is through competitive binding to the native ligand binding site, although the binding orientation of the drugs at the receptor has been a matter of debate. Here we heterologously express mouse 5-HT3A receptors in Xenopus oocytes and use unnatural amino acid mutagenesis to establish a cation-π interaction for both ondansetron and granisetron to tryptophan 183 in the ligand binding pocket. This cation-π interaction establishes a binding orientation for both ondansetron and granisetron within the binding pocket.

DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES

The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective

PIPERIDINYLHYDROXYETHYLPIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention relates to a compound of the formula (I), or a pharmaceutically acceptable salt thereof, wherein R1-R8 and X, m, and n are defined. Compounds and compositions of the present invention are useful the treatment of atherosclerosis.